To assess the ability of muSRK-015P to improve muscle mass and function in SMA, we utilized the SMNΔ7 mouse model of SMA, modifying disease severity by treating mice with varying doses of the small molecule SMN2 splice modulator SMN-C1 (22,38,66). Here, SMN2 is linked to proximal spinal muscular atrophy.